Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07523217

Poly-L-Lactic Acid in Atrophic Acne Scars

Poly-L-Lactic Acid: A Comparative Study of Injectable and Thread-Based Delivery in Atrophic Acne Scars

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
52 (estimated)
Sponsor
Zagazig University · Other Government
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

Background: Management of atrophic acne scars remains challenging due to their heterogeneous morphology and suboptimal response to conventional therapies. Poly-L-lactic acid (PLLA), a biostimulatory agent, promotes neocollagenesis and has emerged as a promising therapeutic option. However, comparative data on different delivery modalities of PLLA and their effects on dermal remodeling and skin physiology remain limited. Objective: To compare two delivery modalities of PLLA (injectable versus mono-thread) and evaluate their effects on dermal remodeling, clinical outcomes, and safety in atrophic acne scars. Methods: This prospective split-face study included 24 patients with atrophic acne scars. The right facial side was treated with a single session of PLLA mono-threads, while the left side received two sessions of injectable PLLA at 6-week intervals. Clinical outcomes were assessed using Goodman and Baron's qualitative and quantitative grading systems over a 3-month follow-up period.

Conditions

Interventions

TypeNameDescription
DRUGinjectable PLLAThe vial was reconstituted with 8 mL of bacteriostatic sterile water for injection (BSWFI). After at least 2 hours, 2 mL of lidocaine (1-2%) with epinephrine was added, making the total solution volume 10 mL. One hour later, the vial was gently shaken, and the syringes were prepared for injection. The injection was given using 28-G needles beneath each scar with a serial injection technique during each session.
DRUGPLLA threadsOn the right side of the face, PLLA threads were used in a single session. Approximately 8-10 Everline PLLA mono-threads

Timeline

Start date
2024-03-15
Primary completion
2027-03-15
Completion
2027-03-15
First posted
2026-04-13
Last updated
2026-04-13

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07523217. Inclusion in this directory is not an endorsement.